ReviewThe Journal of clinical investigation2016
Advances in β cell replacement and regeneration strategies for treating diabetes.
Review in The Journal of clinical investigation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Mesenchymal stem cell transplantation in newly diagnosed type-1 diabetes patients: a phase I/II randomized placebo-controlled clinical trial.Stem cell research & therapy · 2022Trial
- Genetic recording of pancreatic beta cell proliferation.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- miR-302 regulates pancreatic progenitor pool and pancreatic size.Biology open · 2026Article
- Mitochondrial development and remodeling occur at pancreatic progenitor stage during induction of stem cell-derived islet organoids.Frontiers in endocrinology · 2026Article
- Review
- Advanced therapy to cure diabetes: mission impossible is now possible?Frontiers in cell and developmental biology · 2024Review
- Ginseng extract improves pancreatic islet injury and promotes β-cell regeneration in T2DM mice.Frontiers in pharmacology · 2024Article
- Harnessing gut cells for functional insulin production: Strategies and challenges.Biotechnology notes (Amsterdam, Netherlands) · 2023Review
- A Mini-Review of Current Treatment Approaches and Gene Therapy as Potential Interventions for Diabetes Mellitus Types 1.Advanced biomedical research · 2023Review
- The cultivation conditions affect the aggregation and functionality of β-cell lines alone and in coculture with mesenchymal stromal/stem cells.Engineering in life sciences · 2022Article
- β cell regeneration and novel strategies for treatment of diabetes (Review).Biomedical reports · 2022Review
- The IGFBP3/TMEM219 pathway regulates beta cell homeostasis.Nature communications · 2022Article
- Using single-nucleus RNA-sequencing to interrogate transcriptomic profiles of archived human pancreatic islets.Genome medicine · 2021Article
- In vivo screen identifies a SIK inhibitor that induces β cell proliferation through a transient UPR.Nature metabolism · 2021Article
- ANGPTL8 roles in proliferation, metabolic diseases, hypothyroidism, polycystic ovary syndrome, and signaling pathways.Molecular biology reports · 2021Review
- Clinical Translational Potentials of Stem Cell-Derived Extracellular Vesicles in Type 1 Diabetes.Frontiers in endocrinology · 2021Review
- Mesenchymal stem cells promote pancreatic β-cell regeneration through downregulation of FoxO1 pathway.Stem cell research & therapy · 2020Article
- In vivo generation and regeneration of β cells in zebrafish.Cell regeneration (London, England) · 2020Review
- LSD1 inhibition yields functional insulin-producing cells from human embryonic stem cells.Stem cell research & therapy · 2020Article
- A Network of microRNAs Acts to Promote Cell Cycle Exit and Differentiation of Human Pancreatic Endocrine Cells.iScience · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
In the past decade, new approaches have been explored that are aimed at restoring functional β cell mass as a treatment strategy for diabetes. The two most intensely pursued strategies are β cell replacement through conversion of other cell types and β cell regeneration by enhancement of β cell replication. The approach closest to clinical implementation is the replacement of β cells with human pluripotent stem cell-derived (hPSC-derived) cells, which are currently under investigation in a clinical trial to assess their safety in humans. In addition, there has been success in reprogramming developmentally related cell types into β cells. Reprogramming approaches could find therapeutic applications by inducing β cell conversion in vivo or by reprogramming cells ex vivo followed by implantation. Finally, recent studies have revealed novel pharmacologic targets for stimulating β cell replication. Manipulating these targets or the pathways they regulate could be a strategy for promoting the expansion of residual β cells in diabetic patients. Here, we provide an overview of progress made toward β cell replacement and regeneration and discuss promises and challenges for clinical implementation of these strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.